
Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.

May 7, 2020
An extraordinary amount of global research is underway as the COVID-19 pandemic continues to evolve and spread..
Read article

May 5, 2020
Webinar: A Clinician’s Perspective on Cancer Drugs Development
Cytel's team of oncology trial design and advanced analytics experts are hosting a series of complimentary webinars..
Read article

April 23, 2020
A Clinician’s Perspective on Cancer Drugs Development
Cytel is hosting a webinar, “A Clinician’s Perspective on Cancer Drugs Development”, on April 28, 2020. Our speaker,..
Read article

November 28, 2017
Interview: Clinical Trial Optimization with R
In this blog we turn to some reading matter, and interview Gautier Paux and Alex Dmitrienko about the recent book..
Read article

November 9, 2017
The Cytel Story: In the Co-Founders' Own Words
In this blog we are excited to unveil a new project which we have been hard at work on over the last few months. 2017..
Read article

January 30, 2017
Accelerating development with combined SAD/MAD approach
Single ascending dose (SAD) and multiple ascending dose (MAD) studies are typically the first in human studies. They..
Read article

January 23, 2017
How to get the regulatory green light for your adaptive design?
As a group, Cytel had over 40 successful regulatory interactions last year, many of which supported approvals for..
Read article

April 7, 2016
Blinded SSR in early phase biosimilar studies
Francois Beckers, Global Head of Biostatistics & Epidemiology at Merck KGaA joined us at the East User Group Meeting..
Read article

March 29, 2016
Decision Making in Early Clinical Development
On March 16th and 17th the 5th East User Group Meeting took place in London. This very successful 2 days saw a variety..
Read article


September 4, 2015
Using Simulation for Accelerated Early Phase Drug Development
Our Client's Challenge: Can knowledge of the relationship between biomarkers and clinical endpoints help us to optimize..
Read article
April 23, 2015
Dose-finding with Sequential Parallel Comparison Designs
Last week the Cytel Blog discussed the benefits of using the Adaptive Maximizing Design [AM Design] for dose-finding..
Read article
December 16, 2014
Cultivating Versatility in Statistical Consultants
Richard Branson once wrote: “I have always valued capability over expertise. While you may need to hire specialists for..
Read article
October 14, 2014
7 Reasons to Add a Statistical Consultant to Your Team
We are often asked how statistical consultants can add value to the clinical development process. What do they..
Read article
October 7, 2014
You Own This!
Guest blogger Laurie Halloran is the President and CEO of Halloran Consulting Group, a management consulting firm for..
Read article
September 25, 2014
Part II: The Philosophy Behind a Software Package
A few weeks ago, we posted a synopsis of an event held at ISCB Vienna in which statisticians from Cytel, SAS and..
Read article
September 18, 2014
5 times ‘Keep it Simple’ May Be Bad Advice for Clinical Designers
When designing clinical trials, many trial designers are advised to keep the trial simple. Prima facie, the keep it..
Read article

July 22, 2014
10 Simple Steps to Deciding Whether Your Next Trial Should be Adaptive
PROCYSBI, the first drug to receive FDA approval after following an adaptive population re-assessment design, was one..
Read article

May 19, 2014
Frequentist? Time for an update!
Pantelis Vlachos, PhD, is a Director at Cytel Consulting. He works with a team of experts who regularly assist clinical..
Read article
April 24, 2014
New JAMA Study Confirms Importance of Trial Design for FDA Approval
Here at Cytel we firmly believe that if you don’t get the design of a clinical program right, then nothing else..
Read article